The objective of the Biomedical Prevention Program is to reduce the morbidity and mortality caused by cancer through preventing the occurrence of cancer and to improve survival with early diagnosis. This program contains 37 investigators from 15 departments with over $2.4 million in annual direct support. In addition, we have just received investigation from NCI that we will receive funding of approximately $1 million per year over five years to establish the Great Lakes-New England Clinical and Epidemiology Center.
The aim of the program is to continue to build and support multiple, organ-focused vertically integrated research project consisting of population and clinical epidemiology; risk assessment and education; new biostatistical methodologies to study population clusters and surrogate endpoints, and outcomes assessment. The populations targeted for these programs include the general population and special at-risk groups. The program is organ-oriented with funded vertically integrated projects involving Cancer Center Clinical Programs in gastrointestinal cancers, gynecologic cancers, genitourinary cancers, breast cancer, and skin cancer (melanoma). These programs are integrated across the spectrum of primary through tertiary preventive services. The Biomedical Prevention Program closely integrates with the Socio-Behavioral Prevention Program for the development, validation, and clinical application of educational and behavioral tools, and with the Basic Sciences Division for emphasis upon carcinogenesis biology for early cancer detection and surrogate biomarkers for carcinogenesis endpoints. For the coming grant period, four major themes will be emphasized. First, cancer preventive care will be enhanced through sustaining and building cancer prevention clinics and units located in pleasant community surroundings. These units offer genetic population, social, financial, psychological counseling, early detection screening, and interventions. Second, research logistical support improvements are propose through increased population pools and core facilities. Community focused and multi-institutional programs will be strengthened through NIH and University sponsored collaborative grants. New facilities in DNA and serum banking using existing University resources will be developed and supported. Informatics projects will emphasize web-based clinical data management to support community and multi-institutional consortia and methods to retrieve and analyze genomic and proteomic data relevant to early cancer diagnosis and surrogate biomarkers for carcinogenesis. These efforts are supported by a new UO1 grant from the NCI. Third, enhancement of existing research is proposed through the development and funding of large collaborative grants. Proposed SPOREs in breast and gastrointestinal cancer over the coming grant period and associated program projects or linked grants will be supported by Biomedical Prevention Program investigators. A Transdisciplinary Tobacco Use Research Center (TTURC) is proposed for the smoking cessation section of the lung cancer prevention group. The large program grants enhance the collaborative interactions among all Cancer Center programs and will enhance Cancer Prevention programs. Fourth, targeted research initiatives in ovarian cancer prevention and nutrition sciences are proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-15
Application #
6597038
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2018) Individualized outcome prognostication for patients with laryngeal cancer. Cancer 124:706-716
Maust, Joel D; Frankowski-McGregor, Christy L; Bankhead 3rd, Armand et al. (2018) Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. Mol Cancer Ther 17:2495-2506
Arthur, Anna E; Goss, Amy M; Demark-Wahnefried, Wendy et al. (2018) Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study. Int J Cancer 143:1105-1113
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Akkina, Sarah R; Kim, Roderick Y; Stucken, Chaz L et al. (2018) Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions? Laryngoscope Investig Otolaryngol 3:290-295
Anwar, Talha; Arellano-Garcia, Caroline; Ropa, James et al. (2018) p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat Commun 9:2801
Giraldez, Maria D; Spengler, Ryan M; Etheridge, Alton et al. (2018) Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profiling. Nat Biotechnol 36:746-757
Hartlerode, Andrea J; Regal, Joshua A; Ferguson, David O (2018) Reversible mislocalization of a disease-associated MRE11 splice variant product. Sci Rep 8:10121
Fritsche, Lars G; Gruber, Stephen B; Wu, Zhenke et al. (2018) Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. Am J Hum Genet 102:1048-1061
Haley, Henry R; Shen, Nathan; Qyli, Tonela et al. (2018) Enhanced Bone Metastases in Skeletally Immature Mice. Tomography 4:84-93

Showing the most recent 10 out of 1493 publications